The Yellow Fever drugs in development market research report provides comprehensive information on the therapeutics under development for Yellow Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Yellow Fever. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Yellow Fever and features dormant and discontinued products.
GlobalData tracks 26 drugs in development for Yellow Fever by 25 companies/universities/institutes. The top development phase for Yellow Fever is preclinical with 12 drugs in that stage. The Yellow Fever pipeline has 22 drugs in development by companies and four by universities/ institutes. Some of the companies in the Yellow Fever pipeline products market are: Ennaid Therapeutics, Theravectys and Sanofi.
The key targets in the Yellow Fever pipeline products market include Nonstructural Protein 5.
The key mechanisms of action in the Yellow Fever pipeline product include Nonstructural Protein 5 Inhibitor with two drugs in Preclinical. The Yellow Fever pipeline products include six routes of administration with the top ROA being Oral and 11 key molecule types in the Yellow Fever pipeline products market including Vaccine, and Small Molecule.
Yellow Fever overview
Yellow fever is an acute systemic illness (hemorrhagic fever) caused by a flavivirus. It is spread by mosquitoes. Symptoms include irregular heartbeat, bleeding, vomiting, coma, delirium, fever, headache, and muscle aches. There is no specific treatment for yellow fever, so patients are treated to relieve the symptoms.
For a complete picture of Yellow Fever’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
